Third Point Reinsurance (TPRE) is Trading Lower on Unusual Volume for December 21

Equities Staff |

Third Point Reinsurance (TPRE) experienced unusually high volume on Dec. 21, as the stock lost 1.19% to a closing price of $13.34. The stock saw 980,964 shares trade hands over the course of the day on 3,293 trades. Given that the stock’s average daily volume over the last month has been 271,083 shares a day, this represents a pretty substantial spike over the norm.

Third Point Reinsurance has a P/B ratio of 1.05. The stock has traded between $15.45 and $12.88 over the last 52-weeks, its 50-day SMA is now $13.75, and its 200-day SMA $14.15.

Third Point Reinsurance Ltd is a holding company. The Company through its reinsurance subsidiaries provides property and casualty reinsurance coverage to insurance and reinsurance companies.

Headquartered in Pembroke, , Third Point Reinsurance has 23 employees and is currently under the leadership of CEO John R. Berger.

For a complete fundamental analysis analysis of Third Point Reinsurance, check out’s Stock Valuation Analysis report for TPRE. To see the latest independent stock recommendations from’s analysts, visit our Research section.


The Russell 3000 is not well known outside the world of finance, but it’s one of the strongest indices out there for getting a broad sense of the stock market. Unlike the better-known Dow Jones Industrial Average or S&P 500, membership on the Russell 3000 isn’t selected by committee. It’s simply the 3,000 most valuable companies in the country.

With 3,000 stocks making up the index, it gives a broad look at the markets, including the small-and mid-cap companies that aren’t on the Dow or the S&P 500. And with a rules-based system for determining membership, there’s no bias that could potentially limit membership. That’s why many financial professionals will turn to the Russell 3000 long before the better-known indices when trying to take the temperature of the market.

For more news on the financial markets, go to Also, learn more about our independent proprietary equity research reports and our robust do-it-yourself Stock Valuation Analysis reports in our Research section.

All data provided by QuoteMedia and was accurate as of 4:30PM ET.

DISCLOSURE: The views and opinions expressed in this article are those of the authors, and do not represent the views of Readers should not consider statements made by the author as formal recommendations and should consult their financial advisor before making any investment decisions. To read our full disclosure, please go to:


Emerging Growth

PixarBio Corp

PixarBio Corp is a specialty pharmaceutical/biotechnology company focused on pre-clinical and commercial development of novel neurological drug delivery systems for post-operative pain.

Private Markets


The spark hit Jamie when he saw co-workers competing to lose weight. Instead of pizzas and subs, they were eating salads and jogging along the river. Some were sneakily leaving…


Trustify provides trust and safety in both the digital and physical worlds through our vast network of on-demand Private Investigators.By removing the large retainers and high hourly rates that traditional…